AstraZeneca PLC
AZN · Healthcare
$162.47
Cargando gráfico…
Noticias
Últimos titulares de esta acción
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide is entering a competitive obesity market dominated by Novo Nordisk and Eli Lilly. The drug showed up to 20% average weight loss in phase II trials and offers a key advantage with once-monthly or less-frequent dosing compared to weekly injections from competitors. While MariTide trails competitors' efficacy and market presence, the massive obesity market projected to reach $114 billion by 2030 could support multiple players, allowing MariTide to carve out a meaningful position based on convenience and adherence.
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Pacira (PCRX) reported Q2 2026 adjusted earnings of 73 cents per share, beating consensus estimates of 64 cents, with revenues of $192.4 million exceeding expectations. However, the company lowered its 2026 total revenue guidance to $735-$760 million from $745-$770 million following the divestiture of iovera to Zimmer Biomet. Despite the earnings beat, estimates have been trending downward, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech shares have gained 12% since its last earnings report, outperforming the S&P 500. The company beat Q2 2026 earnings estimates with EPS of $1.79 vs. consensus of $1.70, and revenues of $119.2 million from Vyjuvek sales grew 24% year-over-year. Despite upward estimate revisions, the stock holds a Zacks Rank #3 (Hold) with an overall VGM Score of D, suggesting in-line returns ahead.
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's stock has fallen 19.5% in six months due to several clinical and pipeline setbacks, including failed studies for Wainua and Ultomiris, and FDA delays for camizestrant. However, the company maintains solid fundamentals with 16 blockbuster drugs, 15% oncology sales growth, and targets $80 billion in revenues by 2030 with 20 new medicines planned. Despite headwinds from patent expirations and China market uncertainties, analysts recommend staying invested given growth prospects.
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.